Literature DB >> 14499063

Update on overactive bladder: pharmacologic approaches on the horizon.

Eric S Rovner1, Alan J Wein.   

Abstract

Limitations exist with regard to the array of available agents for the pharmacologic therapy of overactive bladder, including issues of efficacy and tolerability. It is clear that the ideal agent for this condition has not been identified. However, several new pharmacologic treatments, including some with novel approaches to drug delivery, have emerged in clinical development over the past few years. These agents include a variety of anticholinergics and others. In initial studies, some of the agents appear to compare favorably with existing therapies. Whether these promising results will hold up when subjected to large-scale, well-controlled clinical trials is unclear.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14499063     DOI: 10.1007/s11934-003-0013-3

Source DB:  PubMed          Journal:  Curr Urol Rep        ISSN: 1527-2737            Impact factor:   3.092


  30 in total

Review 1.  Potential therapeutic targets for treatment of the overactive bladder.

Authors:  D J Sellers; C R Chapple; R Chess-Williams
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

2.  Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland.

Authors:  K Waldeck; B Larsson; K E Andersson
Journal:  J Urol       Date:  1997-03       Impact factor: 7.450

3.  Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.

Authors:  P Van Kerrebroeck; K Kreder; U Jonas; N Zinner; A Wein
Journal:  Urology       Date:  2001-03       Impact factor: 2.649

Review 4.  Beta3-adrenoceptors in human detrusor muscle.

Authors:  Osamu Yamaguchi
Journal:  Urology       Date:  2002-05       Impact factor: 2.649

5.  Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.

Authors:  B Schurch; M Stöhrer; G Kramer; D M Schmid; G Gaul; D Hauri
Journal:  J Urol       Date:  2000-09       Impact factor: 7.450

6.  Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride.

Authors:  I R Katz; L P Sands; W Bilker; S DiFilippo; A Boyce; K D'Angelo
Journal:  J Am Geriatr Soc       Date:  1998-01       Impact factor: 5.562

Review 7.  Trospium chloride--an effective drug in the treatment of overactive bladder and detrusor hyperreflexia.

Authors:  K Höfner; M Oelke; S Machtens; V Grünewald
Journal:  World J Urol       Date:  2001-11       Impact factor: 4.226

8.  Topical oxybutynin chloride for relaxation of dysfunctional bladders.

Authors:  C B Brendler; L C Radebaugh; J L Mohler
Journal:  J Urol       Date:  1989-06       Impact factor: 7.450

9.  Measurement of oxybutynin and its N-desethyl metabolite in plasma, and its application to pharmacokinetic studies in young, elderly and frail elderly volunteers.

Authors:  K M Hughes; J C Lang; R Lazare; D Gordon; S L Stanton; J Malone-Lee; M Geraint
Journal:  Xenobiotica       Date:  1992-07       Impact factor: 1.908

Review 10.  Current and future pharmacological treatment for overactive bladder.

Authors:  Naoki Yoshimura; Michael B Chancellor
Journal:  J Urol       Date:  2002-11       Impact factor: 7.450

View more
  3 in total

Review 1.  Solifenacin in overactive bladder syndrome.

Authors:  Christopher K Payne
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Practical management of nocturia in urology.

Authors:  Myeong Heon Jin; Du Geon Moon
Journal:  Indian J Urol       Date:  2008-07

Review 3.  Preview of new drugs for overactive bladder and incontinence: darifenacin, solifenacin, trospium, and duloxetine.

Authors:  Richard T Kershen; Mike Hsieh
Journal:  Curr Urol Rep       Date:  2004-10       Impact factor: 2.862

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.